Document is current

Article History

Received: 12 April 2024

Revised: 26 November 2024

Accepted: 29 November 2024

First Online: 10 December 2024

Competing interests

: The authors declare the following competing financial interest(s): P.E.L. and T.Z. have previously consulted for Perseis Therapeutics Ltd. P.E.L. is named on PCT application numbers WO 2006/69253 and WO 2008/042435 and US provisional application number 61/059558 and derivatives thereof. V.P., B.B., and P.E.L. are named as inventors on PCT application WO/2018/226155 (PCT/SG2018/050277), Compounds, As Inhibitors of TFF3 Dimerization, Methods and Applications Thereof (and derivatives thereof including US Patent 11,141,402). P.E.L. is an equity holder in Sinotar Pharmaceuticals Ltd., which currently holds PCT/SG2018/050277 and derivatives thereof including issued US Patent No. 11,141,402.

: All the authors agree to publish this paper.

: The authors confirm that all methods were performed in accordance with all relevant guidelines and regulations. All the animal experiments were approved by the Institutional Animal Care and Use Committee of the Laboratory Animal Centre of Peking University Shenzhen Graduate School (permit YW); and ethical approval was obtained from Tsinghua Shenzhen International Graduate School (Number: 37, Year 2019). Informed consent for the use of the LUAD tissue samples and clinical data was obtained by Outdo Bio-tech Co., Ltd. (Shanghai, China).